RxDoctor Payments Data

Vijay Shah, MD

Cardiovascular Disease · Hobart, INNPI 1821084773

Payments from drug & device makers

$4,885in general payments, 2019–2025

Across 208 payments — averaging $23.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$571
  • Johnson & Johnson$371
  • Boston Scientific$358
  • Merck$342
  • Boehringer Ingelheim$307
  • AstraZeneca$288
  • plus $3K from 33 others

What the payments were for

  • Food & beverage$4,71997%
  • Education$1002%
  • Entertainment$661%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,885 in reported general payments places this provider in the 55th percentile of 408 cardiovascular disease providers in Indiana.

See all cardiovascular disease providers in Indiana

Medicare billing

Part B allowed, 2024
$324,939
Medicare patients
984
Services billed
4,785

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban144$166,841
XareltoRivaroxaban103$141,445
JardianceEmpagliflozin61$90,898
EntrestoSacubitril/Valsartan72$89,215
FarxigaDapagliflozin Propanediol18$14,475
BrilintaTicagrelor14$13,801
Potassium Chloride56$13,427
Dabigatran EtexilateDabigatran Etexilate Mesylate33$8,948
Atorvastatin Calcium695$5,460
Metoprolol Succinate206$2,329
Carvedilol331$2,204
Amlodipine Besylate348$1,548
Irbesartan93$1,271
Losartan Potassium226$1,225
Ezetimibe61$1,223

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$62$166,841144 claims
Johnson & JohnsonXarelto$371$141,445103 claims
Boehringer IngelheimJardiance$307$90,89861 claims
NovartisEntresto$571$89,21572 claims
AstraZenecaFarxiga, Brilinta$288$28,27632 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 408 cardiovascular disease providers in Indiana.

Other cardiovascular disease in Hobart

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →